These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 9330784)

  • 21. Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine.
    Tannergren C; Petri N; Knutson L; Hedeland M; Bondesson U; Lennernäs H
    Clin Pharmacol Ther; 2003 Nov; 74(5):423-36. PubMed ID: 14586383
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term effects of Panax ginseng on disposition of fexofenadine in rats in vivo.
    Zhang R; Jie J; Zhou Y; Cao Z; Li W
    Am J Chin Med; 2009; 37(4):657-67. PubMed ID: 19655405
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced systemic exposure of fexofenadine via the intranasal administration of chitosan-coated liposome.
    Qiang F; Shin HJ; Lee BJ; Han HK
    Int J Pharm; 2012 Jul; 430(1-2):161-6. PubMed ID: 22525082
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of rifampin administration on the disposition of fexofenadine.
    Hamman MA; Bruce MA; Haehner-Daniels BD; Hall SD
    Clin Pharmacol Ther; 2001 Mar; 69(3):114-21. PubMed ID: 11240975
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics.
    Yasui-Furukori N; Uno T; Sugawara K; Tateishi T
    Clin Pharmacol Ther; 2005 Jan; 77(1):17-23. PubMed ID: 15637527
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Microdose study of a P-glycoprotein substrate, fexofenadine, using a non-radioisotope-labelled drug and LC/MS/MS.
    Yamazaki A; Kumagai Y; Yamane N; Tozuka Z; Sugiyama Y; Fujita T; Yokota S; Maeda M
    J Clin Pharm Ther; 2010 Apr; 35(2):169-75. PubMed ID: 20456735
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fexofenadine: new preparation. Terfenadine, without cardiotoxicity.
    Prescrire Int; 1999 Feb; 8(39):11-3. PubMed ID: 10557567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic drug interaction between fexofenadine and fluvastatin mediated by organic anion-transporting polypeptides in rats.
    Qiang F; Lee BJ; Lee W; Han HK
    Eur J Pharm Sci; 2009 Jun; 37(3-4):413-7. PubMed ID: 19428223
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improved oral bioavailability of fexofenadine hydrochloride using lipid surfactants: ex vivo, in situ and in vivo studies.
    Eedara BB; Veerareddy PR; Jukanti R; Bandari S
    Drug Dev Ind Pharm; 2014 Aug; 40(8):1030-43. PubMed ID: 23738504
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine.
    Uno T; Shimizu M; Sugawara K; Tateishi T
    Drug Metab Dispos; 2006 Nov; 34(11):1875-9. PubMed ID: 16928786
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Time-dependent interaction between lopinavir/ritonavir and fexofenadine.
    van Heeswijk RP; Bourbeau M; Campbell P; Seguin I; Chauhan BM; Foster BC; Cameron DW
    J Clin Pharmacol; 2006 Jul; 46(7):758-67. PubMed ID: 16809801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism.
    Shon JH; Yoon YR; Hong WS; Nguyen PM; Lee SS; Choi YG; Cha IJ; Shin JG
    Clin Pharmacol Ther; 2005 Aug; 78(2):191-201. PubMed ID: 16084853
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The utility of mixed-effects covariate analysis in rapid selection of doses in pediatric subjects: a case study with fexofenadine hydrochloride.
    Krishna R; Krishnaswami S; Kittner B; Sankoh AJ; Jensen BK
    Biopharm Drug Dispos; 2004 Dec; 25(9):373-87. PubMed ID: 15517550
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans.
    Molimard M; Diquet B; Benedetti MS
    Fundam Clin Pharmacol; 2004 Aug; 18(4):399-411. PubMed ID: 15312146
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combination.
    Kharasch ED; Walker A; Hoffer C; Sheffels P
    J Clin Pharmacol; 2005 Jan; 45(1):79-88. PubMed ID: 15601808
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relative bioavailability of sapropterin from intact and dissolved sapropterin dihydrochloride tablets and the effects of food: a randomized, open-label, crossover study in healthy adults.
    Musson DG; Kramer WG; Foehr ED; Bieberdorf FA; Hornfeldt CS; Kim SS; Dorenbaum A
    Clin Ther; 2010 Feb; 32(2):338-46. PubMed ID: 20206791
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The influence of piperine on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy volunteers.
    Bedada SK; Boga PK
    Eur J Clin Pharmacol; 2017 Mar; 73(3):343-349. PubMed ID: 27981349
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preparation and evaluation of spray-dried hyaluronic acid microspheres for intranasal delivery of fexofenadine hydrochloride.
    Huh Y; Cho HJ; Yoon IS; Choi MK; Kim JS; Oh E; Chung SJ; Shim CK; Kim DD
    Eur J Pharm Sci; 2010 Apr; 40(1):9-15. PubMed ID: 20149868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new fenofibrate formulation: results of six single-dose, clinical studies of bioavailability under fed and fasting conditions.
    Guivarc'h PH; Vachon MG; Fordyce D
    Clin Ther; 2004 Sep; 26(9):1456-69. PubMed ID: 15531008
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic aspects of second-generation H1 antihistamines: a reply to Philpot.
    Estes KS; González MA
    Int J Clin Pharmacol Ther; 1999 Jun; 37(6):310-2. PubMed ID: 10395124
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.